The approval of Sculptra Aesthetic is exciting news for my patients because the downtime is minimal and the results are natural and last up to two years. This is comparatively longer than most other injectables
San Francisco, CA (PRWEB) September 2, 2009
The FDA recently announced approval for Sculptra Aesthetic, to correct shallow to deep smile lines (nasolabial fold) contour deficiencies and other facial wrinkles. Scupltra is a facial injectable that has been in use since 2004 in the treatment of lipoatrophy in HIV patients, but now can be used to minimize facial folds and wrinkles due to aging. According to San Francisco Board-Certified Plastic Surgeon Dr. Scott Mosser, this provides healthy patients with longer-lasting and natural results than some of the other available fillers.
An expert on Sculptra treatment, Mosser has performed hundreds of injections on patients and is optimistic about the potential for the use of Sculptra Aesthetic in San Francisco.
"The approval of Sculptra Aesthetic is exciting news for my patients because the downtime is minimal and the results are natural and last up to two years. This is comparatively longer than most other injectables," Mosser said. "But unlike fillers, Sculptra Aesthetic is a collagen stimulator and can be used to reshape the face with the patient's own collagen."
Through the biological process of neo-synthesis, Sculptra induces the body to produce more of its own collagen. This process, according to Mosser, is what produces a natural appearance. Manufactured by Sanofi-aventis U.S., Scupltra Aesthetic is injected once a month for 2-4 months. As a non-surgical procedure requiring little downtime, treatments are usually performed in relatively short visits to the doctor's office.
Consisting of a synthetic poly-L-lactic acid formula, Sculptra was originally used to counteract facial fat loss in HIV patients by increasing skin thickness and minimizing sunken areas symptomatic of the disease. Employing the same chemical formula, Sculptra Aesthetic is now approved to work in a similar way to minimize the natural loss of fat in healthy aging patients who may not be ready for a facelift.
"Patients who have undergone Sculptra Aesthetic treatments are described as looking younger, but still looking like themselves," Mosser said. "They possess the full, and softer appearance of a more youthful face, but they keep their own natural look."
Mosser expressed his enthusiasm regarding the FDA expanding their approval into the area of facial rejuvenation. "I've been pleased with this treatment in lipoatrophy patients," Mosser said, "and facial aging is really just a natural form of lipoatrophy - slow loss of fat and volume from the face," Mosser said.
Sanofi-aventis U.S. is an affiliate of Sanofi-aventis, a leading global pharmaceutical company headquartered in Paris that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. In addition to Sculptra Aesthetic, the company has produced treatments such as Ambien CR®, Lovenox®, and Plavix®.
Dr. Scott W. Mosser is a Board-Certified plastic surgeon practicing in San Francisco. He is a member of the American Society of Plastic Surgeons and the American Society of Aesthetic Plastic Surgeons.